Bain Capital Life Sciences Fund L.P. 13D and 13G filings for X4 Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 6:55 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Bain Capital Life Sciences Fund L.P. | 16,915,784 11.000% |
4,713,274 (+38.63%) |
Filing |
| 2023-02-14 06:34 am Purchase |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Bain Capital Life Sciences Fund L.P. | 12,202,510 11.000% |
9,315,968 (+322.74%) |
Filing |
| 2022-02-14 06:39 am Purchase |
2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Bain Capital Life Sciences Fund L.P. | 2,886,542 11.000% |
1,238,057 (+75.10%) |
Filing |